DECN.US Decision Diagnostics
- Market cap
- USD 35.8K
- P/E
- -
- P/B
- 2.72x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2021.
Is DECN.US undervalued?
Graham numberThe Graham number of Decision Diagnostics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Decision Diagnostics fundamental analysis
No fundamental analysis for Decision Diagnostics yet.
Decision Diagnostics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Decision Diagnostics
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measureme…
Full company profileDecision Diagnostics financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Decision Diagnostics annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.9M | 12.1M | 6.20M | 427K | 515K | 1.09M | 1.88M | 2.24M | 2.38M | 1.98M | 2.14M |
| Gross Profit | 1.64M | 2.88M | 1.52M | 153K | 294K | 247K | 216K | 780K | 850K | 498K | 477K |
| Operating Income | 784K | -1.01M | -2.70M | -1.27M | -2.47M | -3.01M | -2.46M | -1.85M | -1.29M | -2.10M | -1.58M |
| EBITDA | - | - | - | - | - | - | - | - | -117K | -2.41M | -1.58M |
| Net Income | -472K | -2.12M | -3.08M | -1.84M | -2.77M | -3.18M | -2.99M | -2.24M | -3.13M | -29.7M | -2.44M |
| EPS | - | - | - | - | - | - | - | - | -0.02 | -0.08 | -3.39 |
| Balance Sheet | |||||||||||
| Total Assets | 4.70M | 4.61M | 4.14M | 4.13M | 3.36M | 6.22M | 5.13M | 4.19M | 5.31M | 5.65M | 5.34M |
| Total Liabilities | 2.33M | 2.74M | 3.29M | 4.06M | 2.74M | 3.86M | 3.49M | 3.09M | 5.22M | 5.17M | 5.40M |
| Shareholders' Equity | 2.37M | 1.87M | 852K | 63.4K | 623K | 2.36M | 1.64M | 1.09M | 87.6K | 484K | -52.1K |
| Cash & Short-term Investments | 220K | 14.9K | 85.4K | 1.75M | 627K | 1.35M | 1.09M | 359K | 114K | 522K | 211K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -600K | -209K | 9.88K | -1.48M | -1.22M | -2.88M | -1.56M | -1.32M | -1.11M | -1.40M | -1.45M |
| Capital Expenditure | 0.00 | 64.9K | 64.9K | 261K | 261K | 476K | 64.9K | 75.0K | 116K | 0.00 | 49.2K |
| Free Cash Flow | - | - | - | - | - | - | - | - | -1.23M | -1.40M | -1.50M |
| Ratios | |||||||||||
| ROE | -19.9% | -113.2% | -361.9% | -2,904.7% | -444.5% | -134.8% | -182.4% | -205.1% | -3,576.3% | -6,135.0% | - |
| ROA | -10.0% | -45.9% | -74.4% | -44.6% | -82.5% | -51.1% | -58.3% | -53.5% | -59.0% | -524.8% | -45.6% |
| Net Profit Margin | -2.5% | -17.5% | -49.7% | -431.6% | -538.1% | -291.0% | -159.1% | -100.2% | -131.7% | -1,499.1% | -113.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Decision Diagnostics dividends
Decision Diagnostics has not paid dividends in the last 9 fiscal years.
Last stock split: 1.1:1 on Dec 28, 2011.
Who owns Decision Diagnostics
Ownership data of Decision Diagnostics is not available yet.
Decision Diagnostics company profile
- Company name
- Decision Diagnostics
- Ticker
- DECN.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 6
- Fiscal year end
- December
- Address
- 2660 Townsgate Road, Westlake Village, CA, United States, 91361
- Phone
- 805 446 1973
- Website
- decisiondiagnostics.co
About Decision Diagnostics
Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.
Decision Diagnostics management
1- Mr. Keith M. BermanCEO, CFO, Secretary & Director · born 1953